Free-text search
Articles per year:
Content Types
-
GLP-1 drugs spark unexpected interest among perfume giants
The appetite-suppressing effects of weight-loss drugs are well known. But could they also change what people want to smell like? That question has now caught the attention of some of the world's biggest perfume manufacturers.
-
Roche doubles down on Chinese biotech in deal worth up to $15 billion
A year after their first antibody-drug conjugate deal, Roche and China’s Hansoh Pharmaceutical are expanding their partnership. The new agreement covers several cancer programmes and could bring Hansoh more than $15 billion in payments.
-
Saniona moves depression drug closer to first-in-human trial
The Swedish-Danish research company Saniona has submitted an application to the FDA to begin testing its oral drug candidate in patients with major depressive disorder.
-
Ulf Landegren: From scientific discovery to successful companies
He is a scientist, inventor and entrepreneur with a string of successful companies to his name. Now, Ulf Landegren, a professor at Uppsala University, is to receive a newly established award – in memory of a kindred spirit.
-
Danish health minister: Europe must act on China
Danish politicians and medtech industry representatives are calling for closer cooperation between hospitals and companies to boost innovation. Danish Health Minister Ida Auken also warns that Europe must act to keep pace with growing competition from China.
-
GSK to cut 1,200 jobs in Belgium
More than 1,200 jobs at UK pharma giant GSK are at risk in Belgium as part of a major cost-cutting drive.
-
Modus shares halve after safety-related trial pause
Swedish biotech Modus Therapeutics has temporarily paused recruitment to its Phase IIa trial in anaemia associated with chronic kidney disease following a serious event in a patient. The company’s share price halved after the announcement.
-
Swedish electrode technology moves from lab to patients
Fractions of a millimetre can determine whether deep brain stimulation relieves symptoms or causes side effects. Now, after 20 years of research, scientists at Lund University are preparing to test Swedish-developed technology using ultra-thin electrodes in patients for the first time.
-
Oncopeptides raises SEK 100 million after brain cancer breakthrough
Swedish biotech Oncopeptides is raising SEK 100 million through a directed share issue. The announcement comes days after the company reported progress with its peptide-drug conjugate (PDC) platform in a new area: glioblastoma.
-
Ambu expands their bronchoscopy offering
Ambu's bronchoscope offering has been cleared for use in the pediatric segment.
-
Xbrane reaches milestone with biosimilar to blockbuster cancer drug
Swedish biotech Xbrane is taking another step in developing a biosimilar to Bristol Myers Squibb’s blockbuster cancer drug Opdivo. All patients have now been enrolled in the pivotal trial, bringing the company closer to a potential multibillion-dollar market.
-
Bristol Myers Squibb reports dual Phase III success
Bristol Myers Squibb has reported positive late-stage results for drug candidates targeting idiopathic pulmonary fibrosis and neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).
-
Pfizer wins new FDA approval for Tukysa in breast cancer
Pfizer is strengthening its position in HER2-positive breast cancer. The FDA has approved Tukysa as a first-line maintenance treatment after a phase III trial showed that the combination extended progression-free survival by 8.6 months.
-
Roche's Tecentriq gets FDA nod after strong colon cancer data
A combination of Tecentriq and chemotherapy cut the risk of recurrence or death by half in patients with stage III colon cancer and dMMR tumours. The results have now paved the way for a new FDA approval.
-
Gothenburg researcher aims to launch CAR-T trial for childhood brain tumours
A year ago, Lars Karlsson was named Childhood Cancer Researcher of the Year for his work in the US on CAR-T therapy for children with the aggressive brain tumour diffuse intrinsic pontine glioma, or DIPG. The next step is to work on launching a clinical trial in Gothenburg for children in Sweden.
-
Björn Arvidsson: “We skip the most important step after research”
In Sweden, we are proud of our research – and rightly so. We invest substantial resources and have internationally recognised strengths in life science. But when we debate how research should be translated into real-world value, we often make a strange leap: straight from research to implementation in healthcare. Björn Arvidsson explores the missing step in this column.
-
Nobel laureate’s CRISPR biotech shuts down as funding runs out
Caribou Biosciences was one of the early companies to embrace CRISPR gene-editing technology. Now, the biotech is being forced to halt development of its cancer therapies, despite having a candidate ready for phase III.
-
Mirror-image molecule discoveries win Nobel Prize in Chemistry
The 2026 Nobel Prize in Chemistry is awarded to French chemist Henri B. Kagan and Japanese chemist Kenso Soai for discoveries that explain how chemical reactions can produce molecules with only one of two possible mirror-image forms.
-
Forbion raises €2.3bn in record life science fundraising
Dutch life science investor Forbion has raised 2.3 billion euros – capital that could provide funding for around 30 biotech companies.
-
Natural Cycles sharpens Nordic focus with new regional chief
After nearly a decade at Natural Cycles, Sofie Askervall has stepped into the newly created role of Head of Nordics. “Right now, we are looking closely at Norway,” she says.
-
Medivir’s second act: three drugs to enter Phase 2
As recently as last autumn, the situation was critical, with cash reserves dwindling and the share price falling. Today, Medivir is well funded, its ownership structure has been strengthened, and three fully funded Phase 2 programmes are moving forward.“We are in a strong position now,” says CEO Jens Lindberg.
-
AstraZeneca opens $1bn R&D centre in US
AstraZeneca has now opened its new research and development centre in Cambridge, Massachusetts – an investment of nearly 1 billion dollars.
-
Omnio raises €2.9m for chronic wound therapy
Swedish biotech company Omnio has secured €2.9 million from existing investors and shareholders. The funding will be used to advance its plasminogen-based biological therapy for chronic wounds into first-in-human clinical studies.
-
New AI model could reduce unnecessary surgery for women
Every misjudged ovarian abnormality costs time, money and unnecessary anxiety. A new AI model may offer a solution – once it is fully implemented into the patient pathway.
BREAKING